LENZ Therapeutics (LENZ) Cash from Financing Activities (2020 - 2026)
LENZ Therapeutics (LENZ) posted quarterly Cash from Financing Activities of $14000.0 for Q1 2026, down 68.18% year-over-year from $44000.0 in Q1 2025, and down 99.99% quarter-over-quarter from $122.6 million in Q4 2025.
LENZ Therapeutics (LENZ) Cash from Financing Activities (2020 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Cash from Financing Activities for 7 consecutive years, with $14000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 68.18% year-over-year to $14000.0; the TTM figure through Mar 2026 stood at $149.7 million (up 438.97% YoY), while the FY2025 annual figure was $149.7 million, down 24.75% from the prior year.
- Cash from Financing Activities eased to $14000.0 in Q1 2026 per LENZ's latest filing, from $122.6 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $171.3 million in Q1 2024 and bottomed at -$2.1 million in Q2 2024.
- Historically, Cash from Financing Activities has averaged $28.7 million across 5 years, with a median of $244000.0 in 2022.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities plunged 883.2% — and 2025, when it jumped 231249.06%.
- LENZ Therapeutics' Cash from Financing Activities stood at $244000.0 in 2022, then slumped by 883.2% to -$1.9 million in 2023, then jumped by 102.77% to $53000.0 in 2024, then surged by 231249.06% to $122.6 million in 2025, then sank by 99.99% to $14000.0 in 2026.
- Business Quant data shows LENZ's Cash from Financing Activities at $14000.0 in Q1 2026, $122.6 million in Q4 2025, and $598000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | LENZ Therapeutics | 147.30 Mn | 147.30 Mn | 5.21 Mn | 395,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 395,000.00 |
| Jun 30, 2026 | 395,000.00 |
| Mar 31, 2026 | 14,000.00 |
| Mar 31, 2026 | 14,000.00 |
| Dec 31, 2025 | 122.62 Mn |
| Dec 31, 2025 | 122.62 Mn |
| Sep 30, 2025 | 598,000.00 |
| Sep 30, 2025 | 598,000.00 |
| Jun 30, 2025 | 26.49 Mn |
| Jun 30, 2025 | 26.49 Mn |
| Mar 31, 2025 | 44,000.00 |
| Mar 31, 2025 | 44,000.00 |
| Dec 31, 2024 | 53,000.00 |
| Dec 31, 2024 | 53,000.00 |
| Sep 30, 2024 | 29.82 Mn |
| Sep 30, 2024 | 29.82 Mn |
| Jun 30, 2024 | -2.14 Mn |
| Jun 30, 2024 | -2.14 Mn |
| Mar 31, 2024 | 171.27 Mn |
| Mar 31, 2024 | 171.27 Mn |